CIMAvax, is a therapeutic vaccine against non-small cell lung cancer in advanced stages.
Pharmaceutical form: Injectable suspension for intradermal use (ID)
Therapeutic indications: Treatment of patients with non-small cell lung carcinoma (NSCLC), in advanced stages (IIIb or IV), with objective clinical response or stable disease, after oncospecific treatment of first-line chemotherapy / radiation therapy, such as switch maintenance.
Cancer treatment with the therapeutic vaccine CIMAvax-EGF ® can contribute to significantly prolong the survival time of patients and their quality of life, bringing the fatal course of this disease closer to the course of non-communicable chronic diseases, where the patient undergoes their treatment for life.
This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary lung.
Request to be treated »